Tumor treating induced fields: a new treatment option for patients with glioblastoma
TTIF significantly inhibited the proliferation of U87 cells both <i>in vitro</i> and <i>in vivo</i>. Consequently, TTIF emerges as a potential treatment option for patients with progressive or metastatic GBM.
Authors
- Zhiqiang Zou (ORCID: https://orcid.org/0000-0002-4349-3242)
- T T Meng
- Jinfang Yang
- Xue Yang (ORCID: https://orcid.org/0000-0001-8182-9504)
- Hong Zhao (ORCID: https://orcid.org/0000-0001-9148-0158)
- Zehao Cai
- Zhe Yang (ORCID: https://orcid.org/0000-0001-6797-4190)
- Zhongyuan He (ORCID: https://orcid.org/0000-0002-6194-0720)
- Ying Wang (ORCID: https://orcid.org/0000-0002-0154-6991)
- Ye Li (ORCID: https://orcid.org/0000-0001-7727-0875)
- Feng Chen (ORCID: https://orcid.org/0000-0002-2699-7190)
- Can Wang (ORCID: https://orcid.org/0000-0003-3575-5975)
- Wenbin Li (ORCID: https://orcid.org/0000-0003-2801-6322)
- Hao Zheng (ORCID: https://orcid.org/0000-0001-7193-6242)
- Tong Xiao (ORCID: https://orcid.org/0000-0001-9723-8821)
- Hanwen Zhao (ORCID: https://orcid.org/0009-0009-0530-391X)
- Yang Zhi
- C. Niu (ORCID: https://orcid.org/0009-0006-2639-3617)
Institutions
- Capital Medical University (CN)
- Kunshan Govisionox Optoelectronic (China) (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2024-10-17
- DOI
- https://doi.org/10.3389/fneur.2024.1413236
- Citations
- 3
- Primary Topic
- Neuroscience and Neural Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.80